Neoplasms Clinical Trial
Official title:
Sorafenib Administered Using a High-dose, Pulsatile Regimen in Patients With Advanced Solid Malignancies: a Phase I Exposure Escalation Study
Sorafenib is an oral anticancer drug and inhibits multiple protein kinases important for tumor growth and metastases, including VEGFR, PDGFR, and RAF kinases. In daily clinical practice it is currently used at a dose of 400 mg twice daily in a continuous schedule. In this phase I study patients will be treated with a new dosing schedule of sorafenib: i.e. a high-dose, pulsatile schedule. The tolerability and safety of this new schedule is examined in exposure escalation cohorts based on a target plasma AUC0-12h (area under the curve). Exposure escalation cohorts are used instead of conventional dose escalation cohorts because the effect of a drug is dependent of its AUC levels and large differences in plasma sorafenib AUC0-12h have previously been shown between patients treated at the same dose level. Using pharmacokinetic monitoring, the sorafenib dose will be adjusted to a target plasma AUC0-12h. The escalation cohorts consist of 3-6 patients per exposure level starting with a target plasma sorafenib AUC0-12h level of 25-50 mg/L/h. After the determination of the maximum tolerated AUC0-12h, 10 additional patients will be entered into an expansion cohort. In the expansion cohort the patients will be treated with a weekly pulse of sorafenib at the maximum tolerated AUC0-12h for further assessment of safety and preliminary exploration of efficacy.
Rationale: Preclinical research showed improved efficacy of sorafenib when given in a
high-dose, pulsatile schedule compared with conventional (lower dose) continuous scheduling
as a result of higher peak concentrations in the tumor. In this phase I study patients will
be treated with high-dose, pulsatile sorafenib in exposure escalation cohorts. Exposure
escalations cohorts are based on a target plasma AUC0-12h (area under the curve) and are used
instead of conventional dose escalation cohorts because the effect of a drug is dependent of
its AUC levels and large differences in plasma sorafenib AUC0-12h have previously been shown
between patients treated at the same dose level.
Primary Objectives:
- To determine the maximum tolerated plasma AUC0-12h of high-dose sorafenib administered
in a weekly, pulsatile schedule.
- To assess the safety and tolerability of high-dose, pulsatile sorafenib.
Secondary Objectives:
- To determine the pharmacokinetic behaviour of sorafenib and its major active metabolite
pyridine N-oxide when administered in a weekly, pulsatile schedule.
- To determine a recommended phase II plasma AUC0-12h of high-dose sorafenib in a weekly
pulsatile schedule.
- Preliminary assessment of the efficacy of high-dose, pulsatile sorafenib administered at
the maximum tolerated plasma AUC0-12h.
- To determine skin and intratumoral concentrations of sorafenib and their correlation
with plasma and whole blood concentrations.
- To select 1-2 optimal time points from the AUC0-12h data to determine sorafenib exposure
using a finger puncture.
Study design: A single center, open-label, phase I study of high-dose, pulsatile sorafenib
administered in exposure escalation cohorts.
Study population: Adult patients with locally advanced or metastatic disease for whom no
standard therapy exists.
Treatment: Patients will be treated in exposure escalation cohorts with high-dose sorafenib
administered in a weekly pulsatile schedule. Using pharmacokinetic monitoring, the sorafenib
dose will be adjusted to a target plasma AUC0-12h. The escalation cohorts consist of 3-6
patients per exposure level starting with a target plasma sorafenib AUC0-12h level of 25-50
mg/L/h. After the determination of the maximum tolerated AUC0-12h, 10 additional patients
will be entered into an expansion cohort. In the expansion cohort the patients will be
treated with a weekly pulse of sorafenib at the maximum tolerated AUC0-12h for further
assessment of safety and preliminary exploration of efficacy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT02909348 -
Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
|